ALPS Advisors’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-37,356
| Closed | -$1.77M | – | 1011 |
|
|
2025
Q3 | $1.77M | Sell |
37,356
-5,573
| -13% | -$270K | 0.01% | 408 |
|
|
2025
Q2 | $2.29M | Sell |
42,929
-15,376
| -26% | -$699K | 0.01% | 349 |
|
|
2025
Q1 | $2.36M | Buy |
58,305
+1,865
| +3% | +$79.1K | 0.01% | 327 |
|
|
2024
Q4 | $1.57M | Buy |
56,440
+3,405
| +6% | +$103K | 0.01% | 380 |
|
|
2024
Q3 | $1.52M | Sell |
53,035
-904
| -2% | -$23.6K | 0.01% | 400 |
|
|
2024
Q2 | $1.27M | Buy |
53,939
+14,230
| +36% | +$304K | 0.01% | 416 |
|
|
2024
Q1 | $1M | Buy |
39,709
+2,477
| +7% | +$59.5K | 0.01% | 485 |
|
|
2023
Q4 | $869K | Sell |
37,232
-3,776
| -9% | -$74.5K | 0.01% | 514 |
|
|
2023
Q3 | $2.07M | Buy |
41,008
+343
| +0.8% | +$16K | 0.02% | 316 |
|
|
2023
Q2 | $1.9M | Buy |
40,665
+9,851
| +32% | +$451K | 0.02% | 318 |
|
|
2023
Q1 | $1.18M | Sell |
30,814
-911
| -3% | -$40.6K | 0.01% | 419 |
|
|
2022
Q4 | $1.74M | Buy |
31,725
+11,177
| +54% | +$479K | 0.02% | 327 |
|
|
2022
Q3 | $700K | Sell |
20,548
-229
| -1% | -$3.5K | 0.01% | 540 |
|
|
2022
Q2 | $196K | Sell |
20,777
-15,207
| -42% | -$159K | ﹤0.01% | 996 |
|
|
2022
Q1 | $511K | Sell |
35,984
-4,389
| -11% | -$76.9K | 0.01% | 428 |
|
|
2021
Q4 | $854K | Sell |
40,373
-2,356
| -6% | -$52.3K | 0.01% | 382 |
|
|
2021
Q3 | $955K | Sell |
42,729
-3,143
| -7% | -$71.1K | 0.01% | 397 |
|
|
2021
Q2 | $1.14M | Sell |
45,872
-16,942
| -27% | -$476K | 0.01% | 389 |
|
|
2021
Q1 | $1.82M | Buy |
62,814
+92
| +0.1% | +$2.79K | 0.02% | 326 |
|
|
2020
Q4 | $1.62M | Buy |
62,722
+18,473
| +42% | +$514K | 0.02% | 338 |
|
|
2020
Q3 | $1.36M | Buy |
44,249
+5,136
| +13% | +$179K | 0.02% | 288 |
|
|
2020
Q2 | $975K | Sell |
39,113
-12,805
| -25% | -$293K | 0.01% | 317 |
|
|
2020
Q1 | $1.1M | Sell |
51,918
-6,057
| -10% | -$130K | 0.02% | 264 |
|
|
2019
Q4 | $1.29M | Buy |
+57,975
| New | +$1.2M | 0.01% | 279 |
|
Other funds holding AKRO
ALPS Advisors's AKRO Position: Q4 2025 in Review
ALPS Advisors sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 37,356 shares — an estimated $1.77M sold.
ALPS Advisors first reported a position in AKRO in Q4 2019 and held it in 24 quarters. The position peaked at $2.36M in Q1 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- ALPS Advisors reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- ALPS Advisors sold 37,356 Akero Therapeutics shares in Q4 2025, an estimated $1.77M.
- ALPS Advisors first reported a position in Akero Therapeutics in Q4 2019 and held it in 24 quarters.
- ALPS Advisors's Akero Therapeutics position peaked at $2.36M in Q1 2025.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on ALPS Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.